eTheRNA immunotherapies NV specializes in the development of mRNA-based immunotherapies aimed at enhancing the human immune system's response to cancer and infectious diseases. The company's innovative TriMix technology specifically targets dendritic cells, which play a crucial role in initiating immune responses. By harnessing this technology, eTheRNA seeks to provide more effective and safer treatment options for patients with conditions such as melanoma and triple-negative breast cancer. Founded in 2013 and headquartered in Niel, Belgium, eTheRNA has established a strategic partnership with China Grand Pharmaceutical and Healthcare Holdings Limited to further its research and development efforts. The company is dedicated to advancing the field of immunotherapy to improve patient outcomes.
Xilis, Inc. is an oncology and precision health company that focuses on improving cancer diagnosis and treatment. Founded in 2019 and based in Chapel Hill, North Carolina, Xilis utilizes advanced organoid technologies, specifically micro-organoids, to create thousands of 3D replicas of a patient's tumor within six days. This innovative approach allows for rapid diagnostics and personalized drug screening, enabling healthcare providers to identify the most effective treatments for individual patients. The company's platform supports scalable, patient-derived models that facilitate high-throughput drug discovery, ultimately assisting physicians and pharmaceutical companies in developing tailored therapies at a reduced cost.
ImCheck Therapeutics SAS is a biopharmaceutical company based in Marseille, France, founded in 2015. The company specializes in the development of immunotherapeutics aimed at addressing severe unmet medical needs, primarily in the field of immuno-oncology. ImCheck focuses on creating immuno-modulatory antibodies that target members of the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. Its research and development efforts are directed toward treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company's innovative approach positions it at the forefront of next-generation immunotherapy solutions for patients suffering from solid tumors.
Ariceum Therapeutics is a privately held radiopharmaceutical firm in the clinical stage that specializes in the detection and targeted treatment of aggressive malignancies, such as neuroendocrine and other hard-to-treat cancers. 177Lu-satoreotide tetraxetan (Satoreotide), the company's primary targeted systemic radiopharmaceutical therapy, is an antagonist of the somatostatin type 2 receptor (SSTR2), which is overexpressed in many neuroendocrine tumors. For the simultaneous diagnosis and targeted radionuclide treatment of neuroendocrine malignancies, some aggressive tumors, and childhood cancer, which currently offers few treatment choices and a poor prognosis, we are developing satoreotide as a "theranostic" pair.
AviadoBio mission is to transform the lives of people living with neurodegenerative disorders by developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The Company’s technology is based on pioneering research from King’s College London and the UK Dementia Research Institute.
HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment. The company's platform helps to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases, leverages a database of hotspot structures, harnessing the power of data science in its multidisciplinary approach to drug discovery enabling patients to get treatment against several diseases.
Egle Therapeutics SAS, a biotechnology company, develops immunotherapies targeting immune suppressor regulatory T-cells for oncology and autoimmune diseases. It develops Treg modulating drug pipeline, which includes computationally designed resurfaced IL-2 proprietary variants to engage or dis-engage Tregs. The company was founded in 2020 and is based in Paris, France.
Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company's leading programs include AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining sustained calcium levels in the blood, and AZP-3404, which features a novel mechanism of action that may help restore fat and glucose metabolism. Through its innovative approach, Amolyt Pharma seeks to provide effective treatments for patients suffering from critical and rare metabolic conditions.
Cardior Pharmaceuticals GmbH is a biotechnology company based in Hanover, Germany, established in 2016. The company specializes in developing non-coding RNA-based therapeutics aimed at treating and preventing heart disease, which is a leading cause of mortality in the western world. Its primary focus is on CDR-132X, an oligonucleotide-based inhibitor that targets a specific microRNA, which serves as a molecular master switch regulating pathological changes in the heart due to stress or injury. Cardior Pharmaceuticals is committed to discovering and clinically validating innovative therapies that address the underlying causes of cardiac dysfunction, ultimately striving to improve patients' health and quality of life.
Visus Therapeutics is a clinical-stage company focused on developing innovative ophthalmic therapies aimed at enhancing vision for individuals globally. The company is known for its presbyopia-correcting eye drops, which are designed to provide temporary relief from the loss of near vision associated with presbyopia. Additionally, Visus Therapeutics is engaged in the development of various ophthalmic product candidates targeting conditions such as ocular surface disease, glaucoma, and age-related macular degeneration. Through its research and product offerings, the company seeks to address significant unmet needs in vision care.
T-knife is a biotechnology company focused on developing T cell receptor therapies aimed at treating cancer. Utilizing a humanized T cell receptor (TCR) mice platform, the company is capable of carrying human TCRαβ gene loci and recombining a diverse array of human TCRs. This innovative approach facilitates the efficient generation and virtual selection of T cell receptors tailored for specific human tumor antigens, enhancing the potential for effective cancer therapies. Through its advanced technology, T-knife aims to improve treatment options for patients battling cancer.
Provider of radiology and radiotherapy treatment services intended for imaging diagnostics. The company offers radiology diagnostics, therapy and radiation treatments for malignant and benign diseases as well as supports radiological and nuclear medicine practices as a financial investor and professional management partner on the path of succession planning, creating added value for doctors, employees, referrers and patients through central and local process optimization.
Xilis, Inc. is an oncology and precision health company that focuses on improving cancer diagnosis and treatment. Founded in 2019 and based in Chapel Hill, North Carolina, Xilis utilizes advanced organoid technologies, specifically micro-organoids, to create thousands of 3D replicas of a patient's tumor within six days. This innovative approach allows for rapid diagnostics and personalized drug screening, enabling healthcare providers to identify the most effective treatments for individual patients. The company's platform supports scalable, patient-derived models that facilitate high-throughput drug discovery, ultimately assisting physicians and pharmaceutical companies in developing tailored therapies at a reduced cost.
PAREXEL International Corporation is a biopharmaceutical services company that supports the pharmaceutical, biotechnology, and medical device industries globally. Founded in 1983 and headquartered in Waltham, Massachusetts, the company operates through three main segments: Clinical Research Services (CRS), PAREXEL Consulting and Medical Communications Services (PCMS), and Perceptive Informatics. The CRS segment specializes in managing various aspects of clinical trials, including study design, patient recruitment, data management, and pharmacovigilance. The PCMS segment offers consulting services in areas such as drug development, regulatory affairs, and market access, assisting clients with product launch strategies and commercialization challenges. The Perceptive segment focuses on technology solutions, providing services like medical imaging, systems integration, and data management tools. By delivering a comprehensive range of services, PAREXEL aims to facilitate scientific discoveries and enhance the drug development process for its clients.
Onward is developing an Implantable Neuro-stimulation System (INS) with real-time motion feedback and uses training tools to rehabilitate patients suffering from neurological disorders such as spinal cord injury (SCI).
XyloCor Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapies for cardiovascular diseases, particularly advanced coronary artery disease. Established in 2013 and based in Newtown Square, Pennsylvania, the company is working on innovative treatments such as XC001, an investigational gene therapy aimed at patients suffering from refractory angina who have limited treatment options, and XC002, which targets cardiac tissue regeneration in individuals with compromised heart function due to past heart attacks. XyloCor's approach involves stimulating the formation of new coronary blood vessels to improve blood supply to areas of the heart that are inadequately perfused, thereby offering potential pain relief and improved outcomes for patients who have exhausted conventional pharmacologic therapies.
Neurent Medical Limited is a medical device company based in Galway, Ireland, specializing in the development of innovative treatments for rhinitis. Founded in 2015, the company has created a single-use, minimally invasive device designed for ENT surgeons to address both allergic and non-allergic rhinitis. This hand-held, radio-frequency device is introduced through the nostrils into the nasal cavity under direct endoscopic visualization. It employs a microelectrode array to deliver targeted energy, interrupting the autonomic function of the mucosal structures in the nasal cavities. This approach helps reverse the inflammatory cascade, allowing for effective treatment in an office setting while minimizing the complications and costs commonly associated with traditional surgical procedures.
Vico Therapeutics B.V. is a biotechnology company based in Leiden, the Netherlands, founded in 2019. It specializes in developing RNA modulating therapies aimed at treating rare neurological disorders. The company's primary focus includes spinocerebellar ataxias, Huntington's disease, and Rett syndrome, which are characterized by progressive neurological decline and developmental challenges. Vico Therapeutics is committed to discovering and delivering innovative treatments that address the unmet medical needs of patients suffering from these severe conditions. Through its research and development efforts, the company seeks to provide effective therapeutic options for individuals affected by these disorders.
VarmX B.V., a biotechnology company, develops therapies in the field of hemostasis and thrombosis. It develops PseudoXa, a therapeutic protein that is used to stop bleeding of patients who use blood thinners. The company was founded in 2016 and is based in Leiden, the Netherlands.
Cybin is a biopharmaceutical company dedicated to developing safe and effective therapeutics using psychedelic and medicinal mushrooms. The company focuses on creating psilocybin-based products in regions where such substances are permitted, while also conducting clinical studies across North America and other areas through collaborations with academic and institutional partners. Cybin's efforts encompass the advancement of psychedelic-based therapies, innovative delivery mechanisms, and the development of novel compounds aimed at addressing a range of mental health issues, including various psychiatric and neurological conditions.
Arvelle Therapeutics GmbH is a biopharmaceutical company based in Zug, Switzerland, founded in 2019. The company focuses on developing and commercializing innovative treatments for patients with central nervous system (CNS) disorders. Its primary product is cenobamate, an investigational antiepileptic drug aimed at providing effective solutions for patients suffering from focal seizures. By targeting debilitating neurological and neuromuscular diseases, Arvelle Therapeutics aims to enhance the quality of care available to clinicians and their patients.
Kiadis Pharma N.V. is a biopharmaceutical company based in Amsterdam, specializing in cell-based immunotherapy products for blood cancer treatment. The company is developing K-NK002, currently in Phase II clinical trials, as an adjunctive immunotherapeutic for blood cancer patients undergoing haploidentical hematopoietic stem cell transplantation with the post-transplant cyclophosphamide protocol. K-NK003 is another product in Phase I/II trials, targeting patients with acute myeloid leukemia relapse or refractory cases. Additionally, Kiadis Pharma is working on K-NK00X, a preclinical NK-cell therapy candidate aimed at treating various solid tumors. The company has established collaborations for the development of a combination therapy involving monoclonal antibodies and natural killer cells to address COVID-19. Kiadis Pharma focuses on addressing the complications and limitations associated with hematopoietic stem cell transplants, offering novel treatment options for terminally ill cancer patients with significant unmet medical needs.
FoRx Therapeutics AG is a biotechnology company based in Basel, Switzerland, founded in 2019. It specializes in developing innovative therapeutics for cancer treatment by targeting key molecular pathways involved in DNA replication stress. The company aims to create first-in-class compounds that represent a novel approach in the fight against cancer, focusing on drugging specific molecular targets associated with this replication stress. Through its research and development efforts, FoRx Therapeutics seeks to contribute to the advancement of targeted anticancer drugs within the healthcare industry.
Private Equity Round in 2020
SHL Group, based in Zug, Switzerland, specializes in the design, development, and manufacturing of advanced drug delivery systems, including auto injectors, pen injectors, and inhaler systems. Founded in 1989, the company provides comprehensive services, such as final assembly, labeling, and packaging, for pharmaceutical and biotech firms globally. SHL Group prioritizes compliance with strict regulations and upholds high-quality standards in its operations. The company emphasizes the importance of talent development and collaboration among its employees to enhance productivity and customer satisfaction. By focusing on these core principles, SHL Group aims to deliver superior business outcomes while maintaining professionalism in all aspects of its work.
Mabtech AB is a biotechnology company based in Stockholm, Sweden, founded in 1986. The company specializes in the development, manufacturing, and marketing of monoclonal antibodies and various assay kits, including those for enzyme-linked immunoassays such as ELISA, ELISpot, and FluoroSpot. Mabtech's product range includes monoclonal antibodies for a variety of applications, as well as specialized kits for detecting cytokines and other immunological molecules in biological samples from multiple species, including humans and various animals. The company aims to support the global scientific community by providing efficient tools that streamline the biomedical research process. Mabtech operates internationally, with locations in the United States, Australia, Germany, and France, and offers its products online. It is a subsidiary of Mabtech Group AB.
ImCheck Therapeutics SAS is a biopharmaceutical company based in Marseille, France, founded in 2015. The company specializes in the development of immunotherapeutics aimed at addressing severe unmet medical needs, primarily in the field of immuno-oncology. ImCheck focuses on creating immuno-modulatory antibodies that target members of the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. Its research and development efforts are directed toward treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company's innovative approach positions it at the forefront of next-generation immunotherapy solutions for patients suffering from solid tumors.
Galderma S.A. is a global company specializing in the manufacture and distribution of medical, consumer skin health, and dermatology products. Founded in 1981 and headquartered in Lausanne, Switzerland, Galderma offers a wide range of solutions including prescription medicines, medical aesthetics, and skincare products. Its extensive product portfolio addresses various dermatological conditions such as acne, rosacea, psoriasis, and skin cancer, with well-known brands like Epiduo®, Differin®, and Restylane®. The company operates through a network of 33 wholly-owned affiliates and distributors in approximately 80 countries, employing around 6,600 people. Galderma emphasizes innovation in meeting the dermatological needs of individuals and healthcare professionals, with research and development, and manufacturing sites located across multiple regions including Europe, Asia-Pacific, and the Americas.
Pharvaris B.V. is a clinical-stage company based in Leiden, the Netherlands, focused on the discovery and development of oral bradykinin B2 receptor antagonists for the treatment of hereditary angioedema (HAE) and other conditions linked to B2 receptor activity. Established in 2015, the company aims to provide new therapeutic options that eliminate the need for injections. Its lead drug candidate, PHA121, is a novel small-molecule antagonist currently undergoing Phase 1 clinical trials. Pharvaris benefits from the expertise of its co-founders, including an inventor of icatibant, which is a previously developed treatment for HAE. The company is dedicated to advancing alternatives to existing therapies, enhancing the quality of life for patients with HAE.
Nkarta Therapeutics is a biopharmaceutical company focused on developing engineered natural killer (NK) cell therapies for cancer treatment. Founded in 2015 and headquartered in South San Francisco, California, Nkarta aims to enhance the efficacy and tolerability of cell therapies, addressing both hematologic and solid tumor malignancies. The company's approach utilizes chimeric antigen receptors on NK cells, enabling them to recognize and attack tumor cells more effectively. Nkarta's lead product candidates include NKX101, designed to harness innate NK cell biology for cancer detection and destruction, and NKX019, targeting the CD19 antigen to treat various B cell malignancies. By leveraging its NK expansion platform and proprietary cell engineering technologies, Nkarta seeks to provide a more potent and accessible treatment option, capitalizing on the natural ability of NK cells to identify and eliminate abnormal cells while minimizing side effects typically associated with other therapies.
Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company's leading programs include AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining sustained calcium levels in the blood, and AZP-3404, which features a novel mechanism of action that may help restore fat and glucose metabolism. Through its innovative approach, Amolyt Pharma seeks to provide effective treatments for patients suffering from critical and rare metabolic conditions.
AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derived peptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.
Snipr Biome ApS, founded in 2017 and based in Copenhagen, Denmark, is a biotechnology company focused on developing innovative treatments for microbial diseases using CRISPR technology. The company aims to revolutionize healthcare by employing a programmable approach to target and eliminate harmful bacteria in vivo. By leveraging the adaptive immune system, Snipr Biome's therapies selectively identify and kill bacteria based on their specific DNA sequences. This targeted strategy provides healthcare professionals with advanced options for microbiome engineering, enhancing the precision and efficacy of treatments for bacterial infections.
Arvelle Therapeutics GmbH is a biopharmaceutical company based in Zug, Switzerland, founded in 2019. The company focuses on developing and commercializing innovative treatments for patients with central nervous system (CNS) disorders. Its primary product is cenobamate, an investigational antiepileptic drug aimed at providing effective solutions for patients suffering from focal seizures. By targeting debilitating neurological and neuromuscular diseases, Arvelle Therapeutics aims to enhance the quality of care available to clinicians and their patients.
Atlantic Therapeutics is a medical technology company that develops pelvic floor muscle strengthening and nerve stimulation products.
The company's devices focus on the treatment of all types of incontinence, sexual health dysfunctions, and other associated disorders by strengthening muscles and modulating nerves of the pelvic floor, enabling bladder patients to treat their conditions associated with pelvic floor weakness. Its products are backed by strong clinical evidence and subjected to controlled trials.
It was established in Galway, Galway in 2013.
Karo Pharma is a specialty pharmaceutical company in the Nordics. The company develops and markets products for pharmacies and directly to the healthcare sector. The product portfolio includes over-the-counter and prescription pharmaceuticals as well as medical devices.
XyloCor Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapies for cardiovascular diseases, particularly advanced coronary artery disease. Established in 2013 and based in Newtown Square, Pennsylvania, the company is working on innovative treatments such as XC001, an investigational gene therapy aimed at patients suffering from refractory angina who have limited treatment options, and XC002, which targets cardiac tissue regeneration in individuals with compromised heart function due to past heart attacks. XyloCor's approach involves stimulating the formation of new coronary blood vessels to improve blood supply to areas of the heart that are inadequately perfused, thereby offering potential pain relief and improved outcomes for patients who have exhausted conventional pharmacologic therapies.
HyTest Ltd. is a Finnish biotechnology company based in Turku, specializing in the manufacture of monoclonal antibodies and antigens for the diagnostic industry. Founded in 1994, the company develops high-quality immunological reagents for various clinical applications, including cardiac markers, infectious diseases, metabolic syndrome, and veterinary diagnostics. By providing a diverse range of products, such as monoclonal and polyclonal antibodies, sera, and plasma, HyTest enables clients in the In Vitro Diagnostic (IVD) sector to conduct accurate and reliable testing. The company is committed to expanding its offerings and maintaining high standards in the biotechnology field.
Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative cancer treatments that target DNA damage response (DDR) pathways. Founded in 2015, the company aims to create first-in-class therapies that selectively kill cancer cells by exploiting the mechanisms involved in DNA repair. Its product pipeline features several promising candidates, including DNA polymerase theta (Polθ) and an in-licensed program targeting a novel DDR protein. Artios collaborates with Cancer Research Technology and leading researchers in the field to advance its development efforts. The company's leadership comprises experts with extensive experience in DDR drug discovery, and it has garnered investment from notable entities, including SV Life Sciences and AbbVie Ventures.
Biovian Oy operates as a biopharmaceutical contract development and manufacturing company. It offers process and analytical development services; and GMP services, including microbial fermentation, mammalian cell culture, viral vector production, protein purification, formulation, aseptic fill and finish, analytical quality control, stability studies, and MCB and WCB manufacture and storage, as well as drug product labelling, packaging, storage, and QP release services. The company was founded in 2003 and is based in Turku, Finland.
Rainier Therapeutics is a biotechnology company focused on developing targeted therapies for bladder cancer. The company specializes in Vofatamab, a human monoclonal antibody designed to inhibit the activity of FGFR3 (fibroblast growth factor receptor 3), which is crucial in the treatment of both early-stage and metastatic bladder cancer. Founded in 2010 and based in San Leandro, California, Rainier Therapeutics was previously known as BioClin Therapeutics before rebranding in November 2018. Through its innovative approach, Rainier Therapeutics aims to enhance treatment options for patients suffering from this challenging disease.
Merus N.V. is a clinical-stage immuno-oncology company based in the Netherlands, focused on the discovery and development of bispecific antibody therapeutics. The company's pipeline includes several promising candidates, notably MCLA-128, currently in phase 2 clinical trials for metastatic breast cancer; MCLA-117, in phase I trials for acute myeloid leukemia; and MCLA-158, also in phase I trials for solid tumors. Additionally, Merus is advancing other bispecific antibody candidates, including MCLA-129 and MCLA-145, in collaboration with various pharmaceutical partners. The company employs a unique technology called Oligoclonics, which enables the production of a mixture of therapeutic antibodies from a single cell clone, aimed at targeting common antigens. Merus has established partnerships to enhance its research capabilities, such as its collaboration with Caris Life Sciences for detecting NRG1 fusions in cancer patients. Founded in 2003, Merus is headquartered in Utrecht and is dedicated to developing innovative treatments for cancer.
Orphazyme A/S is a biopharmaceutical company based in Copenhagen, Denmark, that specializes in developing therapies for neurodegenerative orphan diseases, particularly those linked to protein misfolding such as lysosomal storage diseases. Founded in 2009, the company is focused on its lead candidate, Arimoclomol, which is undergoing clinical trials for multiple orphan diseases, including Niemann-Pick disease type C, Gaucher disease, sporadic inclusion body myositis, and amyotrophic lateral sclerosis. Orphazyme’s research is grounded in academic discoveries from its founders at the Danish Cancer Society, and the company has established collaborations with leading academic institutions in Europe and the United States. In addition, Orphazyme has entered a strategic partnership with CombiGene AB to enhance its research and development efforts in the biopharmaceutical sector.
Xeltis AG is a clinical-stage medical device company based in Zurich, Switzerland, with additional research and development facilities in Eindhoven, the Netherlands. Founded in 2006, Xeltis focuses on developing bio-absorbable heart valves and blood vessels that facilitate the body's natural healing processes. Its innovative technology, known as RestoreX, employs a therapeutic approach called Endogenous Tissue Restoration (ETR), which allows patients' own bodies to generate new heart valves. Through ETR, the porous structure of Xeltis' heart valves, made from bioabsorbable polymers, enables tissue to integrate with the implant, gradually forming a fully functional valve while the device itself is absorbed by the body. This groundbreaking approach aims to transform the treatment of heart valve disease by restoring natural heart valve function.
Immunic Therapeutics is a clinical-stage biopharmaceutical company focused on developing selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. Its primary product, IMU-838, is a selective immune modulator currently in Phase 2 clinical trials for ulcerative colitis, relapsing-remitting multiple sclerosis, and Crohn's disease. Additionally, the company is advancing IMU-935, an inverse agonist targeting RORgt, and IMU-856, which aims to restore intestinal barrier function in patients with conditions such as inflammatory bowel disease and irritable bowel syndrome. Immunic Therapeutics is headquartered in New York, New York, and seeks to provide effective treatment options for a range of chronic inflammatory conditions through its innovative drug development initiatives.
Certara Inc. specializes in biosimulation and offers a range of software products and technology-enabled services to support drug discovery, preclinical and clinical research, regulatory submissions, and market access. The company's biosimulation software aids in transforming traditional drug development processes, enabling clients to optimize their R&D efforts and enhance decision-making related to drug development milestones. Certara's services include mechanistic and empirical biosimulation, regulatory strategy, clinical pharmacology, and market access, aimed at guiding biopharmaceutical companies and academic institutions through the complexities of drug approval and commercialization. With a global presence spanning multiple regions, including the Americas, Europe, and Asia Pacific, Certara serves over 1,200 commercial companies and 250 academic institutions, focusing on accelerating the delivery of medicines to patients. Established in 2008, the company is headquartered in Princeton, New Jersey.
Cardior Pharmaceuticals GmbH is a biotechnology company based in Hanover, Germany, established in 2016. The company specializes in developing non-coding RNA-based therapeutics aimed at treating and preventing heart disease, which is a leading cause of mortality in the western world. Its primary focus is on CDR-132X, an oligonucleotide-based inhibitor that targets a specific microRNA, which serves as a molecular master switch regulating pathological changes in the heart due to stress or injury. Cardior Pharmaceuticals is committed to discovering and clinically validating innovative therapies that address the underlying causes of cardiac dysfunction, ultimately striving to improve patients' health and quality of life.
ImCheck Therapeutics SAS is a biopharmaceutical company based in Marseille, France, founded in 2015. The company specializes in the development of immunotherapeutics aimed at addressing severe unmet medical needs, primarily in the field of immuno-oncology. ImCheck focuses on creating immuno-modulatory antibodies that target members of the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. Its research and development efforts are directed toward treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company's innovative approach positions it at the forefront of next-generation immunotherapy solutions for patients suffering from solid tumors.
Rainier Therapeutics is a biotechnology company focused on developing targeted therapies for bladder cancer. The company specializes in Vofatamab, a human monoclonal antibody designed to inhibit the activity of FGFR3 (fibroblast growth factor receptor 3), which is crucial in the treatment of both early-stage and metastatic bladder cancer. Founded in 2010 and based in San Leandro, California, Rainier Therapeutics was previously known as BioClin Therapeutics before rebranding in November 2018. Through its innovative approach, Rainier Therapeutics aims to enhance treatment options for patients suffering from this challenging disease.
OxThera AB is a biopharmaceutical company based in Stockholm, Sweden, with an additional location in Knoxville, Tennessee. Founded in 2005, it focuses on developing treatments for primary and secondary hyperoxaluria, a condition that can lead to kidney stones and impaired kidney function. The company's leading products include Oxabact, an oral formulation of live bacteria designed to enhance the elimination of oxalate produced in the body, and Oxazyme, a recombinant enzyme aimed at managing dietary oxalate and preventing kidney stone formation. Oxabact has received Orphan Drug designations in both Europe and the United States, underscoring its potential in treating primary hyperoxaluria. OxThera holds global patents for its innovative approaches using bacteria and enzymes to address hyperoxaluria, contributing to advancements in kidney disease management.
Immunic Therapeutics is a clinical-stage biopharmaceutical company focused on developing selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. Its primary product, IMU-838, is a selective immune modulator currently in Phase 2 clinical trials for ulcerative colitis, relapsing-remitting multiple sclerosis, and Crohn's disease. Additionally, the company is advancing IMU-935, an inverse agonist targeting RORgt, and IMU-856, which aims to restore intestinal barrier function in patients with conditions such as inflammatory bowel disease and irritable bowel syndrome. Immunic Therapeutics is headquartered in New York, New York, and seeks to provide effective treatment options for a range of chronic inflammatory conditions through its innovative drug development initiatives.
Nouscom is a biotechnology company focused on developing innovative immunotherapy solutions for cancer treatment. Headquartered in Basel, Switzerland, with operations in Rome, Italy, the company specializes in engineered viral vector vaccines. Their platform is designed to express long strings of tumor neoantigens, facilitating the induction of strong antitumor T-cell responses to enhance cancer-specific cellular immunity. The leadership team, including experienced entrepreneurs like Prof. Riccardo Cortese, brings a wealth of expertise from previous successful ventures in the field of oncolytic and genetic vaccines.
Onward is developing an Implantable Neuro-stimulation System (INS) with real-time motion feedback and uses training tools to rehabilitate patients suffering from neurological disorders such as spinal cord injury (SCI).
eTheRNA immunotherapies NV specializes in the development of mRNA-based immunotherapies aimed at enhancing the human immune system's response to cancer and infectious diseases. The company's innovative TriMix technology specifically targets dendritic cells, which play a crucial role in initiating immune responses. By harnessing this technology, eTheRNA seeks to provide more effective and safer treatment options for patients with conditions such as melanoma and triple-negative breast cancer. Founded in 2013 and headquartered in Niel, Belgium, eTheRNA has established a strategic partnership with China Grand Pharmaceutical and Healthcare Holdings Limited to further its research and development efforts. The company is dedicated to advancing the field of immunotherapy to improve patient outcomes.
Rainier Therapeutics is a biotechnology company focused on developing targeted therapies for bladder cancer. The company specializes in Vofatamab, a human monoclonal antibody designed to inhibit the activity of FGFR3 (fibroblast growth factor receptor 3), which is crucial in the treatment of both early-stage and metastatic bladder cancer. Founded in 2010 and based in San Leandro, California, Rainier Therapeutics was previously known as BioClin Therapeutics before rebranding in November 2018. Through its innovative approach, Rainier Therapeutics aims to enhance treatment options for patients suffering from this challenging disease.
Pharvaris B.V. is a clinical-stage company based in Leiden, the Netherlands, focused on the discovery and development of oral bradykinin B2 receptor antagonists for the treatment of hereditary angioedema (HAE) and other conditions linked to B2 receptor activity. Established in 2015, the company aims to provide new therapeutic options that eliminate the need for injections. Its lead drug candidate, PHA121, is a novel small-molecule antagonist currently undergoing Phase 1 clinical trials. Pharvaris benefits from the expertise of its co-founders, including an inventor of icatibant, which is a previously developed treatment for HAE. The company is dedicated to advancing alternatives to existing therapies, enhancing the quality of life for patients with HAE.
Xeltis AG is a clinical-stage medical device company based in Zurich, Switzerland, with additional research and development facilities in Eindhoven, the Netherlands. Founded in 2006, Xeltis focuses on developing bio-absorbable heart valves and blood vessels that facilitate the body's natural healing processes. Its innovative technology, known as RestoreX, employs a therapeutic approach called Endogenous Tissue Restoration (ETR), which allows patients' own bodies to generate new heart valves. Through ETR, the porous structure of Xeltis' heart valves, made from bioabsorbable polymers, enables tissue to integrate with the implant, gradually forming a fully functional valve while the device itself is absorbed by the body. This groundbreaking approach aims to transform the treatment of heart valve disease by restoring natural heart valve function.
Sequana Medical is a medical device company based in Zurich, Switzerland, specializing in implantable pump systems designed to manage fluid balance in the body. The company's flagship product, the alfapump, addresses ascites, the accumulation of fluid in the abdominal cavity often associated with advanced liver disease, certain cancers, and congestive heart failure. The alfapump system facilitates the automatic and continuous removal of ascites by transferring excess fluid to the bladder, where it is expelled naturally. Additionally, Sequana Medical offers the alfapump DSR, which targets sodium removal in patients experiencing volume overload due to heart failure. Founded in 2006 and with a strong presence in Germany, Sequana Medical aims to improve the quality of life for patients suffering from fluid overload conditions through innovative treatment solutions.
Kuros Biosciences AG is a Swiss biopharmaceutical company dedicated to the development of innovative products for tissue repair and regeneration. Founded in 2000 as a spin-off from the Eidgenössische Technische Hochschule Zürich, Kuros has built a diverse pipeline based on proprietary technology platforms developed in collaboration with institutions such as the University of Zürich and the California Institute of Technology. The company's offerings include Neuroseal, a biomaterial for dural sealing currently undergoing CE marking review in the EU, and MagnetOs Granules and Putty, approved for orthopedic, spinal, and dental applications in both the EU and the US. Kuros has an active clinical program, having conducted trials involving over 600 patients with promising results in various indications. Furthermore, Kuros has engaged in collaborations to advance its research, including work on CYT003 for oncology. Positioned for growth, Kuros is transitioning towards commercial operations, with plans for additional product approvals in the near future.
Neuravi Limited is a medical device company based in Galway, Ireland, focused on developing clot retrieval devices to restore blood flow in patients who have experienced ischemic strokes caused by arterial blockages in the brain. The company offers the EmboTrap revascularization devices, which are designed for the treatment of acute ischemic strokes and are available in several European countries, including Belgium, Denmark, France, Germany, and Spain. Founded in 2009, Neuravi operates in the emerging neurointerventional device market and collaborates with researchers and clinicians to advance treatment solutions for this serious condition. As of April 2017, Neuravi is a subsidiary of DePuy Ireland Unlimited Company.
Merus N.V. is a clinical-stage immuno-oncology company based in the Netherlands, focused on the discovery and development of bispecific antibody therapeutics. The company's pipeline includes several promising candidates, notably MCLA-128, currently in phase 2 clinical trials for metastatic breast cancer; MCLA-117, in phase I trials for acute myeloid leukemia; and MCLA-158, also in phase I trials for solid tumors. Additionally, Merus is advancing other bispecific antibody candidates, including MCLA-129 and MCLA-145, in collaboration with various pharmaceutical partners. The company employs a unique technology called Oligoclonics, which enables the production of a mixture of therapeutic antibodies from a single cell clone, aimed at targeting common antigens. Merus has established partnerships to enhance its research capabilities, such as its collaboration with Caris Life Sciences for detecting NRG1 fusions in cancer patients. Founded in 2003, Merus is headquartered in Utrecht and is dedicated to developing innovative treatments for cancer.
Xeltis AG is a clinical-stage medical device company based in Zurich, Switzerland, with additional research and development facilities in Eindhoven, the Netherlands. Founded in 2006, Xeltis focuses on developing bio-absorbable heart valves and blood vessels that facilitate the body's natural healing processes. Its innovative technology, known as RestoreX, employs a therapeutic approach called Endogenous Tissue Restoration (ETR), which allows patients' own bodies to generate new heart valves. Through ETR, the porous structure of Xeltis' heart valves, made from bioabsorbable polymers, enables tissue to integrate with the implant, gradually forming a fully functional valve while the device itself is absorbed by the body. This groundbreaking approach aims to transform the treatment of heart valve disease by restoring natural heart valve function.
Curetis N.V. is a commercial-stage molecular diagnostics company based in Holzgerlingen, Germany, specializing in solutions for severe infectious diseases. The company develops and manufactures a range of molecular microbiology products aimed at detecting various pathogens, including bacteria and fungi, as well as identifying genetic markers for antimicrobial resistance. Key offerings include the Unyvero L4 Lysator for sample pre-processing, the Unyvero A50 Analyzer, and the Unyvero C8 Cockpit, which serves as a control panel for these devices. Curetis also provides Unyvero Application Cartridges for syndromic infectious disease testing and the ARES AMR Database, which compiles data on antimicrobial resistance genetics. Its tests cover multiple infections, including pneumonia and urinary tract infections. Founded in 2007, Curetis has established strategic partnerships with companies like MGI Tech Co. Ltd. and Qiagen N.V., enhancing its capabilities in the molecular diagnostics market.
At Affimed, they are committed to improving outcomes for patients with cancer. Their scientific team has been devoted to unlocking the power of the innate immune system for nearly two decades to provide a unqiue approach to fighting cancer. With their unparalleled expertise in innate immunity and innate cell engager-based medicines, they aim to overcome the limitations and challenges faced by current immuno-oncology (I-O) therapies.
Heart Metabolics Limited is focused on developing a pharmaceutical therapy for hypertrophic cardiomyopathy (HCM), a condition characterized by the thickening of the heart muscle, which can lead to heart failure and sudden death. With over 100,000 cases in the United States, HCM often presents more severely in younger individuals, particularly athletes. While existing cardiovascular drugs offer some relief, many patients do not benefit from current treatments. Heart Metabolics is advancing perhexiline, a drug already approved in Australia and New Zealand for angina, as a potential therapy for all forms of HCM. Following encouraging results from phase II clinical trials, the company is preparing to conduct further clinical trials in the U.S. and aims to obtain FDA approval for perhexiline as an orphan drug, a designation it already holds. Through this development, Heart Metabolics seeks to address significant unmet medical needs in HCM treatment.
Hybrigenics Pharma is a bio-pharmaceutical company with a focus on research and development of new targets and therapies against cancer.Hybrigenics Pharma has stopped the development of inecalcitol, a vitamin D receptor agonist.Hybrigenics Pharma's research program investigates the action of enzymes called Deubiquitinating Enzymes (DUBs) in the recycling of onco-proteins and the potential activity of proprietary patented DUB inhibitors against various cancer indications.
Merus N.V. is a clinical-stage immuno-oncology company based in the Netherlands, focused on the discovery and development of bispecific antibody therapeutics. The company's pipeline includes several promising candidates, notably MCLA-128, currently in phase 2 clinical trials for metastatic breast cancer; MCLA-117, in phase I trials for acute myeloid leukemia; and MCLA-158, also in phase I trials for solid tumors. Additionally, Merus is advancing other bispecific antibody candidates, including MCLA-129 and MCLA-145, in collaboration with various pharmaceutical partners. The company employs a unique technology called Oligoclonics, which enables the production of a mixture of therapeutic antibodies from a single cell clone, aimed at targeting common antigens. Merus has established partnerships to enhance its research capabilities, such as its collaboration with Caris Life Sciences for detecting NRG1 fusions in cancer patients. Founded in 2003, Merus is headquartered in Utrecht and is dedicated to developing innovative treatments for cancer.
Terveystalo is the largest healthcare service company in Finland. We offer a wide range of health, occupational health, medical care and research services as well as dental services in nearly 200 locations in more than 70 locations throughout Finland.
Kiadis Pharma N.V. is a biopharmaceutical company based in Amsterdam, specializing in cell-based immunotherapy products for blood cancer treatment. The company is developing K-NK002, currently in Phase II clinical trials, as an adjunctive immunotherapeutic for blood cancer patients undergoing haploidentical hematopoietic stem cell transplantation with the post-transplant cyclophosphamide protocol. K-NK003 is another product in Phase I/II trials, targeting patients with acute myeloid leukemia relapse or refractory cases. Additionally, Kiadis Pharma is working on K-NK00X, a preclinical NK-cell therapy candidate aimed at treating various solid tumors. The company has established collaborations for the development of a combination therapy involving monoclonal antibodies and natural killer cells to address COVID-19. Kiadis Pharma focuses on addressing the complications and limitations associated with hematopoietic stem cell transplants, offering novel treatment options for terminally ill cancer patients with significant unmet medical needs.
At Affimed, they are committed to improving outcomes for patients with cancer. Their scientific team has been devoted to unlocking the power of the innate immune system for nearly two decades to provide a unqiue approach to fighting cancer. With their unparalleled expertise in innate immunity and innate cell engager-based medicines, they aim to overcome the limitations and challenges faced by current immuno-oncology (I-O) therapies.
IlluminOss Medical, Inc. is a medical device company specializing in the development of minimally invasive orthopedic systems for fracture repair and stabilization. Founded in 2007 and based in East Providence, Rhode Island, the company offers a unique technology that utilizes a light-curable polymer within an expandable balloon catheter to create patient-specific intramedullary implants. This innovative approach is particularly beneficial for treating osteoporotic and compromised bone, providing a fast and effective method for bone stabilization. The IlluminOss system is CE-marked and FDA-cleared for use in various anatomical sites, with additional indications currently under review. IlluminOss markets its products through distributors in several countries, including Austria, Germany, Israel, and the United Kingdom.
BSN medical is a prominent manufacturer of medical products headquartered in Luxembourg, specializing in Compression Therapy, Wound Care, and Orthopaedics. The company develops a diverse range of high-quality branded products aimed at providing effective solutions for healthcare providers and patients. BSN medical is committed to addressing the needs of the healthcare market, particularly in the treatment of acute, chronic, and challenging wounds. By integrating advanced technology with its extensive product portfolio, the company strives for seamless therapy progression and improved treatment efficiency. BSN medical's approach emphasizes a holistic network of integrated therapy solutions, supporting a continuum of care across various medical disciplines.
Celladon Corporation, a biotechnology company, develops and manufactures molecular therapies for the treatment of heart failure. Its products include SERCA2a, an enzyme that regulates calcium cycling and contractility in heart muscle cells; and MYDICAR, an enzyme replacement therapy for heart failure. Celladon was founded in 2000 and is based in La Jolla, California.
Prosensa is a biopharmaceutical company that specializes in the discovery, development, and commercialization of RNA-based therapeutics. It is particularly focused on addressing genetic disorders, with a primary emphasis on neuromuscular conditions. The company recognizes significant market opportunities in the healthcare sector for innovative products targeting genetic disorders, anti-infectives, and oncology. To maximize commercial potential, Prosensa plans to leverage its strong intellectual property position while primarily outsourcing its operations to specialized organizations. Through this strategy, the company aims to develop novel therapeutics that can address unmet medical needs in various therapeutic areas.
Vivoryon Therapeutics is a Germany based biopharmaceutical company engaged in the activities of research and development, preclinical and clinical trials. It is focused on the development of therapeutic products for the treatment of Alzheimer's disease and cancer. The company's pipeline products includes PQ912, PQ1565 and PQ-family.
Nexstim Plc is a neuromodulation company based in Helsinki, Finland, that develops and markets non-invasive brain stimulation technologies. The company specializes in image-guided transcranial magnetic stimulation (TMS) through its proprietary SmartFocus technology, which features 3D navigation for both therapeutic and diagnostic purposes. Nexstim offers the NBT system, designed to treat major depressive disorder and chronic neuropathic pain, as well as the NBS system, which is utilized for pre-surgical mapping of the brain's speech and motor cortices. Primarily, the NBS systems are sold to universities and teaching hospitals. Founded in 2000, Nexstim aims to enhance the quality of life for patients with significant unmet clinical needs through its innovative approaches to brain therapy.
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis in Phase 3; immune thrombocytopenia in Phase 3; pemphigus vulgaris in Phase 2; chronic inflammatory demyelinating polyneuropathy in Phase 2; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase 2 clinical stage in hematological cancer indications; and preclinical products, including ARGX-117 with therapeutic potential in both orphan and large autoimmune inflammatory diseases in and ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation and ARGX-115 for cancer immunotherapy, which are in Phase 1 clinical stages; and ARGX-116 for the treatment of dyslipidemia and ARGX-114 for treating fibrosis, which are in preclinical stage. The company has strategic partnership with AbbVie S.À.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was founded in 2008 and is based in Breda, the Netherlands.
Promethera Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies for liver diseases. Founded in 2009 and based in Mont-Saint-Guibert, Belgium, with an office in Tokyo, Japan, the company specializes in cell therapy products, notably HepaStem and H2Stem, which utilize allogeneic progenitor cells derived from healthy human adult livers. Promethera is actively working on treatments for a range of conditions, including acute-on-chronic liver failure, hemophilia, liver fibrosis, non-alcoholic steatohepatitis, liver-based metabolic diseases, and urea cycle disorders. The company also engages in strategic alliances to further its research and development efforts, enhancing its capacity to discover and commercialize effective cell therapies for liver-related ailments.
Kreatech Holding BV is a molecular diagnostics company focused on the development and commercialization of innovative detection products. These are used for diagnostic and research applications in the life sciences and healthcare industry.
Merus N.V. is a clinical-stage immuno-oncology company based in the Netherlands, focused on the discovery and development of bispecific antibody therapeutics. The company's pipeline includes several promising candidates, notably MCLA-128, currently in phase 2 clinical trials for metastatic breast cancer; MCLA-117, in phase I trials for acute myeloid leukemia; and MCLA-158, also in phase I trials for solid tumors. Additionally, Merus is advancing other bispecific antibody candidates, including MCLA-129 and MCLA-145, in collaboration with various pharmaceutical partners. The company employs a unique technology called Oligoclonics, which enables the production of a mixture of therapeutic antibodies from a single cell clone, aimed at targeting common antigens. Merus has established partnerships to enhance its research capabilities, such as its collaboration with Caris Life Sciences for detecting NRG1 fusions in cancer patients. Founded in 2003, Merus is headquartered in Utrecht and is dedicated to developing innovative treatments for cancer.
Cellerix, S.A. is a biotechnology company based in Tres Cantos, Spain, founded in 2004. The company specializes in the development and production of medicinal products that utilize stem cells of adult origin. Cellerix focuses on therapies for gastroenterology, dermatology, and immune-based diseases. Notable products include Cx401, designed for the treatment of complex perianal fistulas, and Cx501, a cell therapy aimed at treating Epidermolysis Bullosa. Through its innovative approaches, Cellerix aims to address significant medical needs in these therapeutic areas.
Curetis N.V. is a commercial-stage molecular diagnostics company based in Holzgerlingen, Germany, specializing in solutions for severe infectious diseases. The company develops and manufactures a range of molecular microbiology products aimed at detecting various pathogens, including bacteria and fungi, as well as identifying genetic markers for antimicrobial resistance. Key offerings include the Unyvero L4 Lysator for sample pre-processing, the Unyvero A50 Analyzer, and the Unyvero C8 Cockpit, which serves as a control panel for these devices. Curetis also provides Unyvero Application Cartridges for syndromic infectious disease testing and the ARES AMR Database, which compiles data on antimicrobial resistance genetics. Its tests cover multiple infections, including pneumonia and urinary tract infections. Founded in 2007, Curetis has established strategic partnerships with companies like MGI Tech Co. Ltd. and Qiagen N.V., enhancing its capabilities in the molecular diagnostics market.
Kreatech Holding BV is a molecular diagnostics company focused on the development and commercialization of innovative detection products. These are used for diagnostic and research applications in the life sciences and healthcare industry.
Trinity Biosystems, Inc. engages in the development and formulation of oral therapeutic proteins. It involves in developing vaccines in the areas of respiratory, digestive, and sexually transmitted diseases, as well as transporting proteins, peptides, and other macromolecules. The company was founded in 2002 and is based in Menlo Park, California.
Cellerix, S.A. is a biotechnology company based in Tres Cantos, Spain, founded in 2004. The company specializes in the development and production of medicinal products that utilize stem cells of adult origin. Cellerix focuses on therapies for gastroenterology, dermatology, and immune-based diseases. Notable products include Cx401, designed for the treatment of complex perianal fistulas, and Cx501, a cell therapy aimed at treating Epidermolysis Bullosa. Through its innovative approaches, Cellerix aims to address significant medical needs in these therapeutic areas.
Vivoryon Therapeutics is a Germany based biopharmaceutical company engaged in the activities of research and development, preclinical and clinical trials. It is focused on the development of therapeutic products for the treatment of Alzheimer's disease and cancer. The company's pipeline products includes PQ912, PQ1565 and PQ-family.
Private Equity Round in 2009
ActoGeniX is a biopharmaceutical company based in Zwijnaarde, Belgium, founded in 2006 by Bernard Coulie and Mark Vaeck. The company specializes in the development and commercialization of innovative biological drugs, utilizing a proprietary technology platform that leverages living non-pathogenic microorganisms for oral delivery of biopharmaceuticals. ActoGeniX aims to address unmet medical needs in gastrointestinal, immunological, and metabolic diseases, contributing to advancements in therapeutic options within these fields.
Vivendy Therapeutics Ltd. is dedicated to developing enzyme replacement therapies for Morbus Morquio, a rare lysosomal storage disease caused by a genetic deficiency. Founded in 2006 and headquartered in Basel, Switzerland, the company has created a specialized recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is engineered to enhance enzyme activity. This modification significantly improves the efficacy of the therapy for MPS IVA, aiming to provide better treatment options for patients affected by this condition.
Syntaxin is a biopharmaceutical company that engineers and develops bacterial-based protein therapeutics for the treatment of neurological, inflammatory and endocrine diseases. The biopharmaceutical company's proprietary technology platform enables the engineering of bacterial proteins by domain substitution, to produce novel cell-specific biotherapeutics that inhibit cell secretion. These products can have therapeutic effects in a wide range of indications.
Hyperion Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutics for orphan diseases, primarily focusing on urea cycle disorders (UCD) and hepatic encephalopathy. Headquartered in Brisbane, California, the company offers RAVICTI, a nitrogen-binding agent for the chronic management of UCD in both adult and pediatric patients, along with BUPHENYL and AMMONAPS therapies targeting specific UCD subtypes. Additionally, Hyperion is working on glycerol phenylbutyrate, an active pharmaceutical ingredient in RAVICTI, aimed at treating hepatic encephalopathy. Founded in 2006, Hyperion operates as a subsidiary of Horizon Pharma USA, Inc. since May 2015, and it remains committed to addressing the needs of underserved patient populations through its innovative treatments.
Nexstim Plc is a neuromodulation company based in Helsinki, Finland, that develops and markets non-invasive brain stimulation technologies. The company specializes in image-guided transcranial magnetic stimulation (TMS) through its proprietary SmartFocus technology, which features 3D navigation for both therapeutic and diagnostic purposes. Nexstim offers the NBT system, designed to treat major depressive disorder and chronic neuropathic pain, as well as the NBS system, which is utilized for pre-surgical mapping of the brain's speech and motor cortices. Primarily, the NBS systems are sold to universities and teaching hospitals. Founded in 2000, Nexstim aims to enhance the quality of life for patients with significant unmet clinical needs through its innovative approaches to brain therapy.
Cellerix, S.A. is a biotechnology company based in Tres Cantos, Spain, founded in 2004. The company specializes in the development and production of medicinal products that utilize stem cells of adult origin. Cellerix focuses on therapies for gastroenterology, dermatology, and immune-based diseases. Notable products include Cx401, designed for the treatment of complex perianal fistulas, and Cx501, a cell therapy aimed at treating Epidermolysis Bullosa. Through its innovative approaches, Cellerix aims to address significant medical needs in these therapeutic areas.
FlowCardia, Inc. is a medical device company founded in 2002 to design and develop a portfolio of innovative, catheter-based technologies to facilitate guidewire crossing of totally occluded coronary and peripheral arteries. Chronic Total Occlusions (CTOs) are considered one of the last major clinical challenges in interventional therapy. The historic absence of safe and effective CTO recanalization devices is a major reason a large number of patients are still referred to coronary and peripheral bypass surgery and lower limb amputation.
BioProcessors is an online platform that assists its clients in the development of drugs. BioProcessors was launched in 2000 and is based in California.
ISTO Technologies, Inc., an orthobiologics company, develops biologic products to regenerate and restore function to damaged cartilage and bone. It offers InQu, a resorbable bone graft extender and substitute; NuQu, a cell-based injectable therapy for disc regeneration; and DeNovo ET, an engineered cartilage implant for the repair and regeneration of knee cartilage. The company provides its products through distributors. ISTO Technologies, Inc. was founded in 1997 and is based in St. Louis, Missouri.
Kiadis Pharma N.V. is a biopharmaceutical company based in Amsterdam, specializing in cell-based immunotherapy products for blood cancer treatment. The company is developing K-NK002, currently in Phase II clinical trials, as an adjunctive immunotherapeutic for blood cancer patients undergoing haploidentical hematopoietic stem cell transplantation with the post-transplant cyclophosphamide protocol. K-NK003 is another product in Phase I/II trials, targeting patients with acute myeloid leukemia relapse or refractory cases. Additionally, Kiadis Pharma is working on K-NK00X, a preclinical NK-cell therapy candidate aimed at treating various solid tumors. The company has established collaborations for the development of a combination therapy involving monoclonal antibodies and natural killer cells to address COVID-19. Kiadis Pharma focuses on addressing the complications and limitations associated with hematopoietic stem cell transplants, offering novel treatment options for terminally ill cancer patients with significant unmet medical needs.
At Affimed, they are committed to improving outcomes for patients with cancer. Their scientific team has been devoted to unlocking the power of the innate immune system for nearly two decades to provide a unqiue approach to fighting cancer. With their unparalleled expertise in innate immunity and innate cell engager-based medicines, they aim to overcome the limitations and challenges faced by current immuno-oncology (I-O) therapies.
Okairos AG is a biopharmaceutical company that specializes in the discovery and development of genetic T-cell vaccines, with a significant focus on combating the hepatitis C virus. The company is also involved in providing health and allied services. Headquartered in Basel, Switzerland, Okairos operates in Rome and Naples, Italy. It has expertise in gene delivery technologies and scalable viral-vector manufacturing processes, which facilitate the advancement of vaccines and advanced therapies. By utilizing state-of-the-art GMP facilities, Okairos supports biotech companies in transitioning their genetic vaccines and medicinal products from preclinical stages to commercial readiness.
ActoGeniX is a biopharmaceutical company based in Zwijnaarde, Belgium, founded in 2006 by Bernard Coulie and Mark Vaeck. The company specializes in the development and commercialization of innovative biological drugs, utilizing a proprietary technology platform that leverages living non-pathogenic microorganisms for oral delivery of biopharmaceuticals. ActoGeniX aims to address unmet medical needs in gastrointestinal, immunological, and metabolic diseases, contributing to advancements in therapeutic options within these fields.
Prosensa is a biopharmaceutical company that specializes in the discovery, development, and commercialization of RNA-based therapeutics. It is particularly focused on addressing genetic disorders, with a primary emphasis on neuromuscular conditions. The company recognizes significant market opportunities in the healthcare sector for innovative products targeting genetic disorders, anti-infectives, and oncology. To maximize commercial potential, Prosensa plans to leverage its strong intellectual property position while primarily outsourcing its operations to specialized organizations. Through this strategy, the company aims to develop novel therapeutics that can address unmet medical needs in various therapeutic areas.
4-Antibody AG develops human antibody drug-discovery platform for generating antibody therapeutics focused on immuno-oncology. Its technology platform Retrocyte Display is designed to generate therapeutic antibody drug candidates incorporating human antibody libraries expressed in mammalian B-lineage lymphocytes. The company also develops preclinical checkpoint antibody programs targeting GITR, OX40, CTLA-4, PD-1, TIM-3, and LAG-3. 4-Antibody AG was founded in 2002 and is based in Basel, Switzerland.